Canada · Medical and donor conditions

Illustrative clinical review room with a microscope, blank records and sample tubes

Canada Surrogacy: Medical and Donor Requirements

Canadian surrogacy rules are easiest to understand as two separate systems: rules for the person carrying the pregnancy, and rules for third-party sperm or ova. The federal Assisted Human Reproduction Act sets a specific age-related restriction for surrogacy, requires written consent for the use of reproductive material, and prohibits certain payments. Separate federal regulations and a Health Canada technical directive establish detailed safety procedures for third-party donor gametes. Those donor rules are not a single nationwide medical eligibility checklist for every gestational carrier. The correct answer depends on the person’s role, the source of the gametes, the donation pathway and the province where treatment takes place.

Start by identifying the role

Before reviewing a clinic’s requirements, identify who contributes the egg and sperm and who carries the pregnancy. The label “surrogate” can describe people with different legal and clinical roles. This matters because the federal donor-safety regime is directed at specified uses of donor sperm and ova; it does not automatically turn every person who carries a pregnancy into a gamete donor. Section 10 of the Act defines the covered uses: generally, sperm intended for use by a female person other than the donor’s spouse, common-law partner or sexual partner; ova intended for use by a female person other than the donor or the donor’s spouse, common-law partner or sexual partner; and ova intended for the donor’s own use as a surrogate. These statutory categories, not the everyday label “third-party donor,” determine whether the regime applies. Ask the clinic to identify the applicable route in writing.

ArrangementLegal distinctionPractical check
Gestational carrier using donor or intended-parent gametesThe carrier carries an embryo created using someone else’s sperm and/or ova. Carrying the pregnancy alone does not make her a donor of the embryo’s gametes.Check the clinic’s separate medical and psychosocial screening for the carrier, and confirm whether each gamete falls within the federal donor-safety regime.
Traditional surrogate who contributes her own ovumThe same person both provides the ovum and carries the pregnancy. The ovum-donor safety rules may therefore apply in addition to the carrier’s clinical assessment.Ask the clinic to identify each applicable donor pathway and document the assessment, tests, consent and release decision.

Requirements for the person carrying the pregnancy

The federal Act creates a narrow but important age rule: no person may counsel or induce a woman to become a surrogate, or perform a medical procedure to assist her to become one, knowing or having reason to believe that she is under 21. For practical planning, treat 21 as the minimum age for a clinic or provider to take those steps, while preserving the statute’s knowledge-or-reason-to-believe condition. This is a conduct-specific prohibition, not a complete statutory medical-eligibility test. The same Act prohibits paying consideration to a surrogate and paying or accepting consideration for arranging surrogacy services. It prohibits purchasing, offering to purchase or advertising for the purchase of sperm or ova from a donor or a person acting on the donor’s behalf. Health Canada’s non-binding administrative policy explains that the Act does not prohibit buying material from a person who is not a donor and is not acting on a donor’s behalf; it also states that clinics and sperm banks may charge for their own services, including storage, transfer and use. The seller’s role and what the fee covers therefore matter; calling a payment a service fee does not automatically make it lawful. The permitted reimbursement of eligible expenses is a separate, tightly documented category, not a licence to disguise compensation. For the purchase prohibition, “purchase” includes acquiring material in exchange for property or services.

The federal provisions reviewed do not set one universal national checklist for a carrier’s BMI, maximum number of previous pregnancies or caesarean births, required previous live birth, medication list, or psychological-test score. That is a carefully limited statement about the federal rules reviewed, not a claim that no provincial law or professional obligation can apply. Clinics may use clinical criteria that are stricter or more detailed than the federal statutory floor. A clinic’s rejection threshold should therefore be described as a clinical or programme rule unless a specific binding legal source supports it. Ask for the written policy and the medical reason for any exclusion rather than assuming it is a federal prohibition.

A carrier assessment commonly addresses obstetric and general medical history, prior pregnancy complications and deliveries, current conditions and medicines, physical examination, infection risks, uterine or other investigations relevant to embryo transfer, and psychosocial readiness and support. The precise tests and thresholds depend on the treating clinician’s assessment, applicable professional standards and the clinic’s protocol. A previous uncomplicated pregnancy may be preferred by a clinic, for example, but it should not be presented as a universal federal statutory condition on the evidence reviewed here. The carrier’s informed consent and any province-specific requirements for the surrogacy arrangement are separate questions from donor-gamete testing.

Third-party donor gametes: binding safety rules

For third-party sperm or ova within the federal safety regime, the donor-suitability assessment is mandatory. Under the Safety of Sperm and Ova Regulations, it includes donor screening, a physical examination and donor testing; repeat donors may require reassessment. A structured questionnaire records relevant information, including age at donation, medical history associated with infectious-disease risk and genetic history relevant to inherited disease. The assessment and its documentation must be handled by the medical director or a physician or nurse practitioner designated under the technical directive. The medical director of the primary establishment must review the results and make the required suitability determination. This is a regulated process, not merely a clinic preference. The genetic-history questionnaire must cover serious autosomal dominant, autosomal recessive or X-linked disease in the donor and across three generations of the donor’s family history; relevant genetic-test results may be used instead, and the genetic-risk assessment must be documented.

Test groupRuleImportant limitation
Required infectious-disease testing for regular-process donor sperm and ovaHIV-1 and HIV-2; hepatitis B (HBV); hepatitis C (HCV); syphilis; Chlamydia trachomatis; Neisseria gonorrhoeae.The exact specimen, test method and timing are governed by the current Health Canada directive. The list is a practical summary, not a substitute for the full directive or the laboratory’s protocol.
Additional or conditional requirementsHTLV-1/HTLV-2 and cytomegalovirus (CMV) testing apply to sperm donors, not ova donors, under the listed directive requirements. West Nile virus testing applies when the seasonal or travel/residence criteria in the directive are met. ABO and Rh status must also be determined before release. For West Nile virus, the travel/residence trigger includes having lived in or travelled to an endemic area during the preceding 56 days.Do not assume every donor has an identical panel. The applicable process, donor type, current directive and relevant exposure history determine which tests and time windows apply.

Timing matters. For regular-process sperm donations, the initial sample for the listed infectious-disease tests must generally be collected within 7 days of obtaining the sperm. For ova, the sample must generally be collected within 30 days before obtaining the ova or within 7 days afterwards, subject to the directive’s specified exceptions. Repeat donors follow additional schedules set out below. Ask the clinic for actual sample dates and the applicable directive version; a record stating only “tested” is not enough to verify compliance. More specifically, regular-process repeat sperm donors must have screening and a physical examination at least every 6 months; tests for chlamydia and gonorrhoea must also be repeated at least every 6 months, while the other specified initial tests are repeated at least 180 days after donation. For directed repeat sperm donors, screening is done at each donation and the listed infectious-disease tests at least every 3 months; if screening increases the risk profile, follow-up testing uses a specimen collected within 7 days of donation. Repeat ova donors are screened and tested at each donation, with a physical examination at least every 6 months.

In the regular process, a donor must be determined unsuitable if a donor-exclusion criterion in the directive is met or the suitability assessment is incomplete. The directive includes certain infectious-disease risk criteria, relevant positive test results and specified serious genetic-disease criteria; the exact criteria and any re-entry pathway must be checked against the current text. Two narrow qualifications matter: for specified positive-test exclusions, the directive permits a later suitability determination only after a negative confirmatory or supplemental test and the required donor re-entry algorithm. It also lets a sperm donor screened under the criteria in force immediately before 8 May 2024 continue to meet those earlier screening requirements. Ask the clinic to document whether either rule applies. Sperm and ova processed under the regular process must remain in quarantine and cannot be distributed or used until the medical director determines the donor is suitable and documents release. A test result by itself is therefore not the whole decision: the record must show the assessment, medical director’s determination and lawful release from quarantine.

Directed donation, consent and donor age

A directed donation is a defined route for a donor and recipient who know each other, where a health professional requests the material from a primary establishment in that context. The regulations still require an assessment, screening, physical examination and testing, with repeat-donor reassessment where applicable; the medical director must review and document the results. Unlike the regular process, the directive’s donor-exclusion criteria do not operate in exactly the same way for a directed donor, but the clinician must address the risk and the recipient must be informed. Before use, the health professional must document a medical opinion, based on the summary document and any risk-mitigating measures, that use would not pose a serious risk to human health and safety; the professional must also document that the recipient was informed of the risks and gave written consent. A separate “exceptional access” route is also tightly limited: it may apply on a health professional’s request where the recipient has previously been exposed to material from that donor at an equivalent or greater risk profile, or where material from that donor previously resulted in a child for the same individual or couple. Before release from quarantine, the medical director of the primary establishment responsible for quarantine must create and sign a summary recording the donor’s age if known, which exceptional-access condition is met, the dates and results of any donor screening, physical examination or testing, and, if the donor was found unsuitable, the reasons with a detailed explanation. Before use, the health professional must document a medical opinion based on that summary and any risk-mitigating measures, and record that the recipient was informed of the risks and gave written consent. Neither route should be assumed available without the clinic confirming the legal basis.

Consent is separate from medical suitability. Section 8 of the Act prohibits using reproductive material to create an embryo without the donor’s written consent in accordance with the regulations. The consent regulations require the donor’s consent to be signed and witnessed and specify the purposes for which the material may be used, including third-party reproductive use. They also require a signed record confirming that the donor was informed in writing before consenting. Separately, section 9 generally prohibits obtaining or using sperm or ova from a donor under 18, except for preservation or where the person reasonably believes the resulting child will be raised by that donor. That narrow exception should not be treated as permission for ordinary third-party donation by a minor. Do not substitute a surrogacy agreement or a clinic intake form for the specific donor-consent documents required by law.

Medical reimbursements are a separate issue

Federal law permits reimbursement only within the categories and conditions set by the regulations. Eligible categories can include certain drugs, devices and health-care products or services recommended in writing by an appropriately authorized professional. Before reimbursing, the payer must obtain a dated, signed declaration and supporting records; receipts are required except for the regulations’ narrow exception for certain private-vehicle transport costs. For lost work-related income, the payer must also obtain a separate dated, signed declaration from the surrogate, evidence of the income she would have earned and a qualified medical practitioner’s written certification that continuing to work may pose a risk to her health or that of the embryo or fetus. The payer must retain all reimbursement records for six years after each reimbursement. Reimbursement is not payment for being a surrogate or a donor, and a medical-expense label cannot make prohibited consideration lawful.

Practical checklist before treatment

Before treatment: ask the clinic for these records

  • Ask the clinic to state in writing whether the arrangement is gestational or traditional and identify who provides each gamete.
  • Request the carrier’s written medical and psychosocial eligibility protocol. Ask which criteria come from binding law, which reflect professional judgment and which are clinic-specific.
  • For every third-party donor, ask whether the regular or directed donation process applies, which version of the Health Canada directive is being used, and which tests were performed and on what dates.
  • Ask how genetic-disease risk was assessed, who signed the suitability summary, and whether the material remains quarantined or has been formally released.
  • Confirm that the required donor consent is signed, witnessed and covers the intended use. For directed donation, ask how risks were explained and how the recipient’s written consent was recorded.
  • Before treatment, obtain province-specific legal advice on any additional rules affecting the carrier, the agreement and the intended parentage process. Keep reimbursement receipts and supporting medical recommendations separately.

Scope and conclusion

The practical conclusion is straightforward: a carrier’s medical suitability is assessed clinically, subject to the federal age restriction and any applicable provincial requirements; third-party donor sperm and ova are subject to a detailed federal safety regime. The applicable province, the donor pathway and whether the carrier contributes her own ovum should be confirmed before treatment. This guide addresses federal medical and gamete-safety rules only; it does not decide intended-parent eligibility, the enforceability of a surrogacy agreement, legal parentage, birth registration, citizenship or cross-border travel. The guide reflects federal law as of 22 October 2026: the consolidated Act and the Safety of Sperm and Ova Regulations are current through 30 September 2026, and the Safety Regulations were last amended on 4 June 2026. Check for later amendments before relying on this guide.

Official legal and government sources

  • Health Canada, Compliance and enforcement policy for the Assisted Human Reproduction Act (POL-0100)
  • Last updated:

    Author: Khachatrian Razmik, LL.M.

    International surrogacy and parentage legal services — LEX SURROGACY by Lex Agency · Author profile · Editorial standards